Lyell Immunopharma, Inc. (LYEL) shareholders
Close on Nov 17, 2026Market cap $334.99MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| James Tananbaum | 19,478,893 | 6.70% | 13G (passive) amendment | Dec 31, 2024 |
| ARCH Venture Fund IX Overage, L.P. Joint filing with ARCH Venture Fund IX, L.P. (17.40%), ARCH Venture Fund XIII, L.P. (17.40%) and 11 more | 5,568,424 | 17.40% | 13G (passive) amendment | Nov 4, 2026 |
| ARCH Venture Partners XIII, L.P. Joint filing with ARCH Venture Fund IX, L.P. (13.90%), ARCH Venture Fund IX Overage, L.P. (13.90%) and 11 more | 3,247,162 | 13.90% | 13G (passive) amendment | Mar 31, 2026 |
| Innovative Cellular Therapeutics Holdings Limited | 3,000,000 | 12.30% | 13G (passive) amendment | May 18, 2026 |
| Robert Nelsen Joint filing with Steven Gillis (13.00%), ARCH Venture Fund IX Overage, L.P. (13.00%) and 10 more | 2,759,072 | 13.00% | 13G (passive) amendment | Sep 30, 2025 |
| Innovative Cellular Therapeutics Holdings Ltd | 1,900,000 | 9.80% | 13G (passive) | Nov 6, 2025 |
| Jeffrey P. Bezos Joint filing with Explore Investments LLC (6.60%) | 1,529,054 | 6.60% | 13G (passive) amendment | Mar 31, 2026 |
| Antonis Indianos Joint filing with Euler Fund, L.P. (6.71%), Euler Managers Limited (6.71%) | 1,426,528 | 6.71% | 13G (passive) | Mar 6, 2026 |
| Explore Investments LLC Joint filing with Jeffrey P. Bezos (5.40%) | 1,040,964 | 5.40% | 13G (passive) | Jul 25, 2025 |
| William H. Gates III Joint filing with Gates Frontier, LLC (5.60%) | 1,040,964 | 5.60% | 13G (passive) | Jul 25, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LYEL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 3,247,162 | 13.25% | $45.53M | – | 4.14% |
| GSK plc | 1,512,659 | 6.17% | $21.25M | – | 3.53% |
| Vanguard Capital Management LLC | 786,774 | 3.21% | $11.05M | +68,619 | 0.00% |
| Orland Properties Ltd | 754,698 | 3.08% | $10.60M | – | 5.25% |
| BlackRock, Inc. | 724,342 | 2.96% | $10.18M | +532,522 | 0.00% |
| Almitas Capital LLC | 581,407 | 2.37% | $8.17M | +3,600 | 1.96% |
| Foresite Capital Management V, LLC | 476,386 | 1.94% | $6.69M | −692 | 1.85% |
| Millennium Management LLC | 367,473 | 1.50% | $5.16M | −91,432 | 0.00% |
| Opaleye Management Inc. | 344,025 | 1.40% | $4.83M | +264,928 | 0.44% |
| venBio Partners LLC | 337,697 | 1.38% | $4.74M | – | 0.91% |
| Geode Capital Management, LLC | 310,636 | 1.27% | $4.37M | +143,656 | 0.00% |
| Alphabet Inc. | 293,256 | 1.20% | $4.12M | – | 0.00% |
| State Street Corp | 185,322 | 0.76% | $2.60M | +112,800 | 0.00% |
| HSG Holding Ltd | 152,299 | 0.62% | $2.14M | – | 0.17% |
| Renaissance Technologies LLC | 130,190 | 0.53% | $1.83M | +13,779 | 0.00% |
| Northern Trust Corp | 118,500 | 0.48% | $1.66M | +88,220 | 0.00% |
| Qube Research & Technologies Ltd | 110,531 | 0.45% | $1.55M | +55,421 | 0.00% |
| Charles Schwab Investment Management Inc | 107,570 | 0.44% | $1.51M | +21,599 | 0.00% |
| Marshall Wace, Llp | 106,300 | 0.43% | $1.49M | −42,216 | 0.00% |
| Velan Capital Investment Management LP | 105,000 | 0.43% | $1.48M | +3,000 | 0.90% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 86 | 12M | 48.9% | 23 / 28 | 19 / 9 | 2M | 2M |
| Q1 2026 | 73 | 12M | 48.9% | 18 / 24 | 8 / 10 | 3M | 0M |
| Q4 2025 | 68 | 11M | 46.9% | 16 / 18 | 16 / 4 | 3M | 1M |
| Q3 2025 | 57 | 10M | 41.7% | 7 / 18 | 16 / 14 | 4M | 1M |
| Q2 2025 | 64 | 7M | 27.8% | 64 / 0 | 0 / 0 | 7M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
76 funds held LYEL in Q2 2026, 78% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LYEL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 604,461 | 2.47% | $8.49M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 226,964 | 0.93% | $3.19M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 163,755 | 0.67% | $2.30M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 103,567 | 0.42% | $1.34M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 89,674 | 0.37% | $1.26M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 67,714 | 0.28% | $1.17M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 67,448 | 0.28% | $1.17M | 0.01% | May 31, 2026 |
| iShares Biotechnology ETF | 54,071 | 0.22% | $759.70K | 0.01% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 31,581 | 0.13% | $443.71K | 0.03% | Jun 30, 2026 |
| Small Cap Value Fund | 28,350 | 0.12% | $398.32K | 0.06% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 25,830 | 0.11% | $447.63K | 0.00% | May 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 23,005 | 0.09% | $398.68K | 0.01% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 22,930 | 0.09% | $296.71K | 0.00% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 22,919 | 0.09% | $397.19K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 21,467 | 0.09% | $372.02K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lynn Seely | President and CEO, Director | 63,354 | 0.26% | Nov 12, 2026 |
| Gary K. Lee | Chief Scientific Officer | 16,091 | 0.07% | Nov 12, 2026 |
| Veronica Sanchez Bulis | VP, Corporate Controller | 14,383 | 0.06% | Nov 12, 2026 |
| Stephen J. Hill | Chief Operating Officer | 16,728 | 0.07% | Nov 12, 2026 |
| Jarrad Mattieu Aguirre | Chief Medical Officer | 19,857 | 0.08% | Oct 13, 2026 |
| David Shook | Chief Medical Officer | 20,423 | 0.08% | Sep 10, 2026 |
| Smital Shah | Chief Fin. and Bus. Officer | – | – | Mar 16, 2026 |
| Mark A. Meltz | General Counsel | – | – | Feb 11, 2026 |
| Charles W. Newton | Chief Financial Officer | 25,306 | 0.10% | Aug 22, 2025 |
| Matthew Lang | Chief Business Officer | 162,500 | 0.66% | Feb 26, 2025 |
| Richard Klausner | Director | 190,557 | 0.78% | Jun 12, 2026 |
| Sumant Ramachandra | Director | 10,000 | 0.04% | Jun 12, 2026 |
| Elizabeth G. Nabel | Director | – | – | Jun 12, 2026 |
| Otis W. Brawley | Director | 1,782 | 0.01% | Jun 12, 2026 |
| William Jl Rieflin | Director | – | – | Jun 12, 2026 |
| Mark Bachleda | Director | – | – | Jun 12, 2026 |
| Cathy Friedman | Director | 16,818 | 0.07% | Jun 12, 2026 |
| ARCH Venture Partners XIII, L.P. | 10% owner | – | – | Nov 5, 2026 |
| Paul L. Berns | 10% owner | 1,426,528 | 5.82% | Nov 5, 2026 |
| ARCH Venture Partners IX, L.P. | 10% owner | – | – | Nov 5, 2026 |
| ARCH Venture Fund IX, L.P. | 10% owner | 36,412,716 | 148.59% | Nov 5, 2026 |
| ARCH Venture Partners IX, LLC | 10% owner | 3,747,790 | 15.29% | Nov 5, 2026 |
| ARCH Venture Partners IX Overage, L.P. | 10% owner | 1,426,528 | 5.82% | Nov 5, 2026 |
| ARCH Venture Fund IX Overage, L.P. | 10% owner | – | – | Nov 5, 2026 |
| Steven Gillis | 10% owner | – | – | Nov 5, 2026 |
| Keith Crandell | 10% owner | 1,820,634 | 7.43% | Nov 5, 2026 |
| Robert Nelsen | 10% owner | 36,412,716 | 148.59% | Nov 5, 2026 |
| Kristina Burow | 10% owner | 938,438 | 3.83% | Nov 5, 2026 |
| Clinton Bybee | 10% owner | – | – | Nov 5, 2026 |
| ARCH Venture Partners XIII, LLC | 10% owner | – | – | Nov 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lynn Seely President and CEO, Director | Nov 10, 2026 | Sale | −545 | $15.93 | $8.68K | 63,354 |
| Stephen J. Hill Chief Operating Officer | Nov 10, 2026 | Sale | −88 | $15.93 | $1.40K | 16,728 |
| Veronica Sanchez Bulis VP, Corporate Controller | Nov 10, 2026 | Sale | −416 | $15.93 | $6.63K | 14,383 |
| Gary K. Lee Chief Scientific Officer | Nov 10, 2026 | Sale | −129 | $15.93 | $2.05K | 16,091 |
| ARCH Venture Partners IX, LLC 10% owner | Nov 4, 2026 | Buy | +2,321,262 | $10.77 | $25.00M | 3,747,790 |
| ARCH Venture Fund XIII, L.P. 10% owner | Nov 4, 2026 | Buy | +2,321,262 | $10.77 | $25.00M | 3,747,790 |
| Jarrad Mattieu Aguirre Chief Medical Officer | Oct 12, 2026 | Sale | −422 | $8.63 | $3.64K | 19,857 |
| David Shook Chief Medical Officer | Sep 10, 2026 | Sale | −500 | $12.70 | $6.35K | 20,423 |
| Gary K. Lee Chief Scientific Officer | Aug 21, 2026 | Sale | −1,457 | $15.54 | $22.64K | 16,220 |
| Stephen J. Hill Chief Operating Officer | Aug 21, 2026 | Sale | −989 | $15.54 | $15.37K | 16,816 |
| Lynn Seely President and CEO, Director | Aug 21, 2026 | Sale | −9,589 | $15.54 | $149.01K | 63,899 |
| Gary K. Lee Chief Scientific Officer | Aug 10, 2026 | Sale | −131 | $14.34 | $1.88K | 17,677 |
| Veronica Sanchez Bulis VP, Corporate Controller | Aug 10, 2026 | Sale | −621 | $14.34 | $8.91K | 14,799 |
| Lynn Seely President and CEO, Director | Aug 10, 2026 | Sale | −390 | $14.34 | $5.59K | 73,488 |
| Stephen J. Hill Chief Operating Officer | Aug 10, 2026 | Sale | −89 | $14.34 | $1.28K | 17,805 |
| Cellular Therapeutics Holdings Ltd Innovative 10% owner | Jul 27, 2026 | Other | −44,000 | – | – | 2,774,980 |
| Cellular Therapeutics Holdings Ltd Innovative 10% owner | Jul 27, 2026 | Other | −38,500 | – | – | 2,818,980 |
| Cellular Therapeutics Holdings Ltd Innovative 10% owner | Jul 17, 2026 | Sale(10b5-1 plan) | −10 | $13.70 | $137 | 2,857,480 |
| Cellular Therapeutics Holdings Ltd Innovative 10% owner | Jul 16, 2026 | Sale(10b5-1 plan) | −10 | $13.73 | $137 | 2,857,490 |
| Cellular Therapeutics Holdings Ltd Innovative 10% owner | Jun 29, 2026 | Other | −76,000 | – | – | 2,857,500 |
| Cellular Therapeutics Holdings Ltd Innovative 10% owner | Jun 15, 2026 | Other | −66,500 | – | – | 2,933,500 |
| David Shook Chief Medical Officer | Jun 10, 2026 | Sale | −1,977 | $12.64 | $24.99K | 20,923 |
| Lynn Seely President and CEO, Director | May 11, 2026 | Sale | −388 | $18.91 | $7.34K | 73,878 |
| Gary K. Lee Chief Scientific Officer | May 11, 2026 | Sale | −130 | $18.92 | $2.46K | 17,808 |
| Stephen J. Hill Chief Operating Officer | May 11, 2026 | Sale | −89 | $18.92 | $1.68K | 17,894 |
| Veronica Sanchez Bulis VP, Corporate Controller | May 11, 2026 | Sale | −217 | $18.91 | $4.10K | 15,420 |
| ARCH Venture Partners IX Overage, L.P. 10% owner | Mar 6, 2026 | Buy | +488,090 | $25.61 | $12.50M | 1,426,528 |
| Paul L. Berns 10% owner | Mar 6, 2026 | Buy | +488,090 | $25.61 | $12.50M | 1,426,528 |
| Stephen J. Hill Chief Operating Officer | Feb 11, 2026 | Sale | −1,236 | $23.39 | $28.91K | 17,795 |
| Gary K. Lee Chief Scientific Officer | Feb 11, 2026 | Sale | −1,671 | $23.39 | $39.08K | 16,938 |
| Lynn Seely President and CEO, Director | Feb 11, 2026 | Sale | −7,455 | $23.39 | $174.37K | 74,266 |
| Gary K. Lee Chief Scientific Officer | Feb 10, 2026 | Sale | −147 | $23.12 | $3.40K | 18,609 |
| Lynn Seely President and CEO, Director | Feb 10, 2026 | Sale | −438 | $23.12 | $10.13K | 81,721 |
| Stephen J. Hill Chief Operating Officer | Feb 10, 2026 | Sale | −109 | $23.12 | $2.52K | 19,031 |
| Veronica Sanchez Bulis VP, Corporate Controller | Feb 10, 2026 | Award | +8,750 | – | – | 15,891 |
| Veronica Sanchez Bulis VP, Corporate Controller | Feb 10, 2026 | Sale | −254 | $23.12 | $5.87K | 15,637 |
| Gary K. Lee Chief Scientific Officer | Feb 9, 2026 | Award | +4,000 | – | – | 18,756 |
| Lynn Seely President and CEO, Director | Feb 9, 2026 | Award | +20,000 | – | – | 82,159 |
| Stephen J. Hill Chief Operating Officer | Feb 9, 2026 | Award | +4,000 | – | – | 19,140 |
| Veronica Sanchez Bulis VP, Corporate Controller | Dec 30, 2025 | Sale | −936 | $32.32 | $30.25K | 7,141 |
| Veronica Sanchez Bulis VP, Corporate Controller | Dec 24, 2025 | Sale | −1,136 | $38.67 | $43.93K | 8,077 |
| Stephen J. Hill Chief Operating Officer | Nov 10, 2025 | Sale | −95 | $16.12 | $1.53K | 15,750 |
| Gary K. Lee Chief Scientific Officer | Nov 10, 2025 | Sale | −138 | $16.16 | $2.23K | 15,366 |
| Lynn Seely President and CEO, Director | Nov 10, 2025 | Sale | −412 | $16.11 | $6.64K | 67,159 |
| Veronica Sanchez Bulis VP, Corporate Controller | Nov 10, 2025 | Sale | −239 | $16.10 | $3.85K | 9,213 |
| Charles W. Newton Chief Financial Officer | Aug 21, 2025 | Sale | −1,453 | $10.54 | $15.31K | 15,306 |
| Lynn Seely President and CEO, Director | Aug 21, 2025 | Sale | −7,257 | $10.54 | $76.49K | 67,571 |
| Gary K. Lee Chief Scientific Officer | Aug 21, 2025 | Sale | −1,453 | $10.54 | $15.31K | 15,504 |
| Stephen J. Hill Chief Operating Officer | Aug 21, 2025 | Sale | −1,004 | $10.54 | $10.58K | 15,845 |
| Charles W. Newton Chief Financial Officer | Aug 20, 2025 | Award | +8,000 | – | – | 16,759 |
| Lynn Seely President and CEO, Director | Aug 20, 2025 | Award | +40,000 | – | – | 74,828 |
| Gary K. Lee Chief Scientific Officer | Aug 20, 2025 | Award | +8,000 | – | – | 16,957 |
| Stephen J. Hill Chief Operating Officer | Aug 20, 2025 | Award | +8,000 | – | – | 16,849 |
| Stephen J. Hill Chief Operating Officer | Aug 12, 2025 | Sale | −94 | $10.34 | $972 | 8,849 |
| Charles W. Newton Chief Financial Officer | Aug 12, 2025 | Sale | −136 | $10.34 | $1.41K | 8,759 |
| Lynn Seely President and CEO, Director | Aug 12, 2025 | Sale | −406 | $10.34 | $4.20K | 34,828 |
| Gary K. Lee Chief Scientific Officer | Aug 12, 2025 | Sale | −136 | $10.34 | $1.41K | 8,957 |
| Stephen J. Hill Chief Operating Officer | Aug 11, 2025 | Sale | −91 | $10.53 | $958 | 8,943 |
| Charles W. Newton Chief Financial Officer | Aug 11, 2025 | Sale | −131 | $10.53 | $1.38K | 8,895 |
| Lynn Seely President and CEO, Director | Aug 11, 2025 | Sale | −391 | $10.53 | $4.12K | 35,234 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lyell Immunopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,558 shares on Aug 31, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Richard Klausner Director | Aug 15, 2023 | 4,485 | $10.27K | Aug 15, 2023 | Restricted Stock Award |
| Richard Klausner Director | Aug 15, 2023 | 4,485 | $10.27K | Aug 15, 2023 | Restricted Stock Award |
| Richard Klausner Director | Aug 15, 2023 | 4,485 | $10.27K | Aug 15, 2023 | Restricted Stock Award |
| Richard Klausner Director | Aug 15, 2023 | 44,565 | $102.05K | Aug 15, 2023 | Restricted Stock Award |
| Richard Klausner Officer, Director | Jul 17, 2023 | 14,500 | $42.05K | Jul 13, 2023 | Restricted Stock Award |
| Richard Klausner Officer, Director | Jul 17, 2023 | 3,300 | $9.57K | Jul 13, 2023 | Restricted Stock Award |
| Richard Klausner Officer, Director | Jul 17, 2023 | 3,300 | $9.57K | Jul 13, 2023 | Restricted Stock Award |
| Richard Klausner Officer, Director | Jul 17, 2023 | 3,300 | $9.57K | Jul 13, 2023 | Restricted Stock Award |
See a number that looks wrong?